National Library of Medicine, Office of Acquisitions Management, Building 38A, Room B1N17, 8600 Rockville Pike, Bethesda, Maryland 20894

A -- REPERFUSION THERAPY SUPPLEMENT POC Valerie M. Syed, Contracting Officer, (301) 496-6546 The National Library of Medicine intends to negotiate on a sole source basis with the New England Medical Center Hospitals, Inc., 750 Washington Street, Boston, MA 02111 under the authority of FAR 6.302. The New England Medical Center Hospitals, Inc. was awarded a two-year contract (N01-LM-0-3519) on July 1, 2000, to develop and assess computer based expedited care measures for suspected heart attack victims. The goal is to administer reperfusion therapy (thrombolysis) as promptly as possible, while avoiding the possibly hazardous consequences of inappropriate administration. Computer based (i.e. informatics based) approaches are intended to facilitate electrocardiogram interpretation prior to arrival at the emergency department and to guide administration of the therapeutic enzyme. Prompt administration is essential; effectiveness diminishes rapidly after onset of symptoms. Inappropriate administration, where no heart attack is evident, risks serious internal hemorrhage. Experimental evidence now suggests that another compound, if administered promptly, can reduce the damage done to the heart, and prolong the period of effectiveness of reperfusion therapy. New England Medical Center Hospitals, Inc. now proposes to add an additional trial arm to the clinical trial under the existing contract to ascertain whether this Glucose Insulin Potassium compound (GIK) can actually improve survival in conjunction with reperfusion. If so, the contribution to health care delivery, and to patient survival rates, could be significant. This enhancement is both timely and cost effective. Necessary clinical and informatics applications for sudden heart attack care have been developed by an experienced, nationally recognized team. In this contract further refinements will be developed, and they will be tried together systematically, from site of attack to hospital bed. The design of the additional trial arm follows the basic procedures that were reviewed for the original proposal. Because the team, cooperative arrangements, and recruitment strategies are already in place, the cost of the GIK trial is minimal. Introducing a new contractor, who would have to redevelop the structures now in place, would add materially in time and cost. This notice of intent, therefore, is not a request for competitive proposals. However, all responsible sources may submit a proposal which will be considered by the National Library of Medicine. See Numbered Note 22.**** Posted 07/26/00 (W-SN478912). (0208)

Loren Data Corp. http://www.ld.com (SYN# 0006 20000728\A-0006.SOL)

| A - Research and Development Index  |  Issue Index |